We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Biosimilar development represents one of the most complex and regulated pathways in modern biopharmaceutical manufacturing. Demonstrating analytical similarity, functional equivalence, and comparability between a proposed biosimilar and its reference product requires rigorous, multi-dimensional characterization across structural, physicochemical, biological, and immunological attributes. Profacgen provides comprehensive Biosimilar & Comparability Services that integrate advanced analytical platforms, functional bioassays, and regulatory-aligned comparability frameworks to support developers throughout the biosimilar lifecycle—from initial analytical similarity assessment through clinical comparability confirmation and post-approval manufacturing change evaluation.
What Challenges Do We Solve?
Complex multi-attribute analytical similarity requirements across structural, functional, and immunological domains
Regulatory expectations for stepwise comparability demonstration aligned with FDA, EMA, and ICH guidelines
Statistical rigor in equivalence testing and quality range establishment for critical quality attributes
Functional similarity assessment bridging in vitro bioactivity and in vivo clinical relevance
Our Core Platforms
Our biosimilar and comparability capabilities are organized into three interconnected platforms, each addressing a critical stage of analytical and functional characterization. These modules can be deployed independently or integrated into a complete comparability workflow.
Mechanism-of-action-based bioactivity evaluation bridging analytical attributes to biological and clinical relevance
Binding affinity and kinetics comparison by SPR and BLI
Cell-based potency assays and reporter gene systems
ADCC, CDC, and immune effector function evaluation
Neutralizing antibody and immunogenicity risk assessment
Application Scenarios
Our Biosimilar & Comparability Services support a broad spectrum of applications across biopharmaceutical development and manufacturing:
Biosimilar Development Programs: Stepwise analytical similarity assessment from physicochemical characterization through functional equivalence to support regulatory submissions under FDA, EMA, and WHO biosimilar pathways
Manufacturing Process Changes: Pre- and post-change comparability studies for cell line changes, scale-up, purification modifications, formulation updates, and site transfers
Post-Approval Change Management: Continued process verification comparability and lifecycle management to maintain regulatory compliance after market authorization
Reference Product Characterization: Extensive lot-to-lot variability profiling to establish quality target ranges and inform biosimilar development strategies
Why Choose Profacgen?
Regulatory-Aligned Methodology: Our comparability frameworks are designed in accordance with FDA, EMA, ICH Q5E, and WHO biosimilar guidelines, ensuring submission-ready data packages.
Integrated Multi-Attribute Characterization: We connect primary structure, higher-order structure, glycosylation, charge variants, aggregates, and functional bioactivity into a unified similarity assessment.
Advanced Statistical Rigor: Equivalence testing, quality range analysis, and tiered attribute assessment provide robust statistical foundations for regulatory decision-making.
Whether you require analytical similarity assessment for an early-stage biosimilar candidate, comparability evaluation for a manufacturing process change, or functional bioassay support for regulatory submission, our Biosimilar & Comparability Services are designed to accelerate your path from development to approval.
Explore our core modules above or contact us to discuss a customized solution tailored to your specific biosimilar or comparability program needs.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
